Analysts Give Strong Buy Rating To This Undervalued Medical Stock (MURA) With Up To 350% Of Share Price Upside

Growth investors love the potential upside in stock trading and it's easy to see why. Buying a stock and watching it increase in value by several hundred or even several thousand percent is a thrill for any investor. If you like growth stocks, you might be interested in a medical stock that analysts, including the team at Raymond James, think has up to 350% upside potential.

Don't Miss:

• Commercial real estate has historically outperformed the stock market, and this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!
• If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it?

Mural Oncology MURA

Mural Oncology is a pharmaceutical company that develops advanced cancer treatments. It was founded in 2018 by medical professionals and entrepreneurs who wanted to explore alternatives to traditional cancer treatments like radiation therapy. Mural Oncology focuses on engineering proteins that enhance the body's ability to fight cancerous tumors.

Mural's leadership believes this is a more effective method of treating cancer that offers the added benefit of reducing the side effects of traditional treatments like radiation therapy. The company's latest innovation, nemvaleukin alfa, is designed to elevate the patient's immune and T-cells' ability to shrink tumors.

See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O’Reilly and Rudy Giuliani are using this platform to create customized gold IRAs to help shield their savings from inflation and economic turbulence. 

It has already undergone a successful clinical trial, which showed promise regarding its safety and effectiveness. There is hope that nemvaleukin-based drugs will be useful in fighting various cancers, including two types of Melanoma and platinum-resistant ovarian cancer (PROC). Two nemvaleukin-based drugs are undergoing clinical trials, with results expected in Q2 2025. This is where it gets interesting.

If those tests are successful, Mural Oncology stock could be set for a massive increase. It's currently trading at only $3.99, but many analysts believe it has the potential to go much higher. Raymond James analyst Laura Prendergast recently rated MURA a "strong buy" and set a 2025 price target of $18 for MURA shares. Mura’s share price would have increased by 351% if it hits her target.

Prendergast justified her bullishness on MURA by saying, "We believe MURA is currently undervalued for the following reasons: 1) lead asset, nemvaleukin, has near-term commercial opportunity that doesn't seem to be on the radar yet for many investors, 2) management and board have notable experience that inspire confidence in the ability to maneuver late-stage drug development/commercial launch/BD execution."

Trending: Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!

Prendergast doesn't see $18 as the ceiling for MURA either. Her analysis noted, "If MURA can execute on [its] catalysts, we anticipate the company could become a major buyout target. We analyzed recent biotech acquisitions with similar 5-year forward sales estimates to MURA. (The) average historical takeout multiple for this peer group is 5x EV/5-year forward sales, which implies a potential deal value of ~$1.2B and a $48 target price for MURA."

Buying MURA at $3.99 and having it reach $18 by the end of 2025 would be a big win. However, anyone who buys MURA at $3.99 will be thrilled if MURA shares hit $48 before a buyout in the next five years. On the other side of the equation, it's important to remember that MURA is a medical stock and its success hinges heavily on positive results from the upcoming clinical trial.

Despite early promise from previous trials, there is always an element of risk when your stock price is riding on upcoming clinical trial results. With that said, the risk is also where the upside comes from. MURA is only trading for $3.99 right now, so the risk is comparatively low compared to the upside. So, if you're looking for a growth stock, kick the tires on MURA. You might like what you see.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. 

A 9% Return In Just 3 Months

EquityMultiple's ‘Alpine Note — Basecamp Series' is turning heads and opening wallets. This short-term note investment offers investors a 9% rate of return (APY) with just a 3 month term and $5K minimum. The Basecamp rate is at a significant spread to t-bills. This healthy rate of return won't last long. With the Fed poised to cut interest rates in the near future, now could be the time to lock in a favorable rate of return with a flexible, relatively liquid investment option. 

What's more, Alpine Note — Basecamp can be rolled into another Alpine Note for compounding returns, or into another of EquityMultiple's rigorously vetted real estate investments, which also carry a minimum investment of just $5K. Basecamp is exclusively open to new investors on the EquityMultiple platform.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.